{"ticker": {"uuid": "0df9ea28-5d7a-45f2-895e-d7204e29445f", "symbol": "DYAI", "name": "Dyadic International Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Price to sales forward of Dyadic International, Inc. \u2013 NASDAQ:DYAI", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPVm1sOVVLdTc2blpaYzZ3UmV4UU5DXzBuQ0ctbElVMnAxUHl3a0R5NjFKa0FuZ1NYZ3Y5UW9nRGlsd2FWTWVlUUNzY3hnRllwNktHWVFqTnU5ZmZYQi1LOGJGWUdwQ1RvWDlOc2g5NUZ1VGo1d2dzR0V3cTM1cGhySTYzY3Q3NjlQVHA1aE5CU3VkRVZXTnBCbXhOcVFSZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T20:33:38+00:00", "published_display": "13 Jul 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T13:30:59+00:00", "published_display": "11 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Q1 2026 Earnings: Continued Losses as Pre-Revenue Company Advances C1 Platform; Shares Rise 4.82% - Interim Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOb0I1LUhDY2JCeWtXOTl6TDlvYXlfU0hVeWVkYkkyQ3NQZ1hUZWV2c1ExRTdXaGJWdXNobVF6M21tTEhSVVdEbHVLV2MxZ2pCNVdTTmRkRnlRbVQwblY5ZFR4VmFPdzJmeDlNbDhqQU5HRmZNTU4ydG1nRFR0TVNCVG00R3VYREQxT0ZYa2lhY1E5SzBFdTdHWk1Say1OSGYybTNuQmFsTjJqb2oyckxmNDJaSmNxNnpaajZSMVBQM0NkTG9yeHpjNGxyblhBSHhSaHlfN0MtSWNteEZGRzFfVmRVVkpyWTlRTklxag?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T17:47:15+00:00", "published_display": "09 Jul 2026 17:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Dyadic(DYAI.US) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQUUhhVDFJeDBxZGZmcjJKU3hzSlZBNVYzdFMxSGZoNW0yeUNwaFUwemJsYmVLWTVuMXZPel95RTlxUl9IOE1xTDNDeWEtcFJuNXE2aGFQenNSM0d0YUY4b1dzekxPeG1UNVUwOERvLVcxaU85Vm5RZUdYby1DMkZhRTRndC1TSEUtbWZPdHoxUWlSMGNJNlBaSg?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-08T19:48:53+00:00", "published_display": "08 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International stock reflects a thin catalyst day. Focus stays on its enzyme platform.", "summary": "Dyadic International (DYAI) stock is focused on its enzyme platform business, with no new catalysts reported. The company utilizes fungal expression and recombinant protein development for industrial and life-science applications. Its value is tied to platform development, licens", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-reflects-a-thin-catalyst-day-focus-stays-on/69714994", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:24:00", "published_display": "07 Jul 2026 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Progresses Multiple Protein Production Partnerships", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-international-progresses-multiple-protein-133230260.html", "source_name": "MT Newswires", "published_at": "2026-07-07T13:32:30+00:00", "published_display": "07 Jul 2026 13:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Collaborations Continue to Validate Dyadic\u2019s C1 Platform and Expands Commercial Potential", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/global-collaborations-continue-validate-dyadic-112500240.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:25:00+00:00", "published_display": "07 Jul 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic says its C1 platform can make antibodies and vaccines faster", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZ2c3UHU4UEI1aWZUNDFPMldmX0hoZkNrM2duSDllTUZwVF95aUVkTVVtRXZhWnMxNW5pNHVoSnlOS3dhWDhyaTZySVpHbkRVT0Fua1lkNGRkRzJpUWVkU1NBMWJoeng5a3VnUXh5d0NJUUhFSExXNEFoZW5jNjYzd19uaFFBLVNkUERXZFFJYm5LWnl3MWUteXAwN2dlUVFJMlBsdXgzaU9aOXVTZF9GV3k4bENEdnN4UUxXejE5Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T11:25:00+00:00", "published_display": "07 Jul 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYAI - Dyadic International Inc, DE Forecast, Target Price", "summary": "This article provides a detailed financial overview of Dyadic International Inc (DYAI), including key metrics such as market capitalization, income, sales, EPS, and various performance indicators. It also lists the last closing price, daily change, and a target price set at $6.00", "url": "https://finviz.com/stock?t=DYAI&ta=1&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T13:47:09", "published_display": "06 Jul 2026 13:47", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francisco Trust (DYAI) amends large convertible note and sells DYADIC shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSS1yT25aUkN5VWVQRkN2NnpkcW4wNnJSX2M4OTB3NUVNUkZFc3FWXzZxYzIzWWZZeWdnTU1WOWNtT2tiV2ZDTzR6U2JtSlVkQ2F2SFgzdE8tVmhsdVZlUTFzUjdTb1dCMkNXa0RmOEcxR3Rkc3JVcGRURUMybWhwaUZMYkN5YmJtZ2ZGQTZtZEJST2F0WEJZandFeW5fT3F0UzJBdm81LXE1QUYzamJCTzh5bVgtaFBiUnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T10:30:45+00:00", "published_display": "06 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYADIC International (NASDAQ: DYAI) trustee reports 11.58% stake in 13G/A", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQX2VPZldCOXMza3dLZ1lvNFpfMXRZNnc1cUwxNTVPcnU2WDNxZUlsRmhLeEQtWkRmM1RReDJZSDN3QlcyUnBKUWRUbkdJQjFsNldFMzFSeFVpY1lYR2E4Y3diRVpNaGtCOU1QM3N0VXBOdk5WVXFMWS1qVEF0Q3cxbmJJWkpXSHVTNXZITkxXbkxVRGJCX2hHaVByajVRcWZSRXY4TXVkMHV0NVZXeFprRFlodkd3ZWlsQUhPbGF6bXp4RnhwQXJ2NXJHNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyadic International Inc For: 6 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONUFCNUVjaUxuRVktMkRkZnJ0MkJMVG1lVGluSktmbDlBZmhoSTlJeF9mLVlKZGROLWJPaFZYWmpvYUd4azJHMnBocThaNjg0U3dTTTd0eW8xOU9ZbTFtQUR6eU9WZ1ZSSkVJam9LM0VWZGZNX1NwRGpLaGRYNFRaZDRseXpHbWgzLVl4SHhmRGJFZzY2R25PUVd1dUliLW1WdWpwTE53?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francisco Trust sells $343,763 in Dyadic International shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOd2JuTzRQcDczeGE2dl9uRk1wWVdCVTFIOHE1YXJMQy1Zb2FHVlVnS1pUTzNtbXFwTTFxWTFBWnNlN2plMlU1RUJmMXQ4NVRNOG9ZSzhTR3NPaUdNXzZrS1c3UEtCUlJ5dTVzNmthd2FOTE9tMmlSMVVNV2xuZU1JQTlaUFdsMlI5ZS1vSlZ3b3lJMjdBNVF6TDVNU1BBQkZtajM5WE42bUZBSHBBT1g1b3M1amtzV3BhZWFGVUhkMWZEUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-international-receives-japan-patent-121307575.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:13:07+00:00", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Expands IP Protection and Business Development Activities in Japan", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-expands-ip-protection-business-112500388.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:25:00+00:00", "published_display": "29 Jun 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan backs Dyadic\u2019s protein technology as it courts partners", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObE5nNThKaWJGSTBRR3dRVnh1YWZSbnZvYl9OczdmM3c1cjFOdHdBQWJmWGNqU21pZndPU1ZORE1hbnVzWmhkdU9sOExQRGlXQmlDX0hLWFlDaHMwYkl5c2Vmb2I4czZSTENTRFFtWUFSd1c5bnJHLU1pUzN0cnRSaDBXMmg1QlR2Qk1rdlk1NlFDX3k5ZHhJVkJMRk5ua3dtTWZkYUR2aTVNRUJyVWFNUl9qSUtPR2o3WmU3SU90NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/interview-president-coo-dyadic-commercializing-124600451.html", "source_name": "TMX Newsfile", "published_at": "2026-06-22T12:46:00+00:00", "published_display": "22 Jun 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (NASDAQ: DYAI) investors OK reverse split, pay plan and auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVXh2NWNLaXdBaGp0emVxOHhtdk9qeWQ4MmwwN1d1TXVsc01ZZUZSNW1SNU9CSy14cmNGOXZSc1pOSGxCVmx3cTY2Z3k2NklpU0NJSi1Xdi1QYzBtODhSSDdoSkVyN2liN0NkSk1iOFFlTEZrdjhOS0RHWlNmeV9keDNjcE15R0hNcDFEYldZSXBndDF1bjNIWDBmMVJUczRGU0VobTNnNlotU2xnelgydXBSSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Dyadic (NASDAQ: DYAI) over bid price and listing shortfalls", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQaHFYWnMyYy1ndWpkUzZtUlI1ZjEtRWxCTF9VejFTMHNFdGJtVENmaTM5emRiMnozXy1tRTZ0STQ1czdhVzdGTlVPYmd0bWdVNVI5RVV5OEo2T2c0dWlGc1F0OWJGaC0tTEF3M0U2Z2NjU2hNQ0NkRUNxNGttdHVqU2dZWTE4N01lQjZOLTJTbklPcXNMTDV1cC1TWG9abXhnaUlsNjJzZFZjUzBnRzRHNHpBUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-highlights-accelerated-interest-c1-112500620.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:25:00+00:00", "published_display": "15 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] DYADIC INTERNATIONAL INC Reports Material Event | DYAI 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSGtydTBlMmRSZEpZUmRHMG9kYlZXUG1weHNseGlIblQtVEQ4Q1ZNcHZpM1BhekFNaWp3clNyOWdzRllDR3BkQkdtR1ZOVXJXMUxSbkVOTlhqaFJzQVF1VmZlT1Q3WUZtbVFoaVFhTXBPc0NyUVNTUHhjY2VVZmlJUThsQ3NvTW90Mm5HaUw4clRvb1VCMVI4M3ZOMkVoQjNsOWR5MkdLNk41NGNqRGFwY0RXVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From viral gene to antibody in 15 days: Dyadic\u2019s Ebola bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNZ0VJd2c3VEpBTDVoeDdjSVBFZ3RUQmtYc0hpU0xnMmtGRWthYS13SWRQdlZFVDdGRnR6d08zNy1tZTNVWjk5Z1VIeFBXLTVxTFltOHJLVzlVVW1CS1R3UVdRem56MmVkV0F2NGwxZEQ1bVJrbGtkNkl0Zm13aXNTNGVaV2FhaVZhMVRjSkhiUEx5YUF3YjlyVGswVnktVmpjTW13MWJhaDgxVC1Ta0FodU1hTDM3ajA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (DYAI) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/18721462-f4d5-3665-bbe9-63e27f22e1cc/dyadic-%28dyai%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-02T16:39:07+00:00", "published_display": "02 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYAI - Dyadic International Inc, DE Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial overview for Dyadic International Inc (DYAI), a healthcare biotechnology company. It includes key financial metrics, recent news headlines, analyst ratings, and insider transaction data. The company's stock closed at $0.8", "url": "https://finviz.com/stock?t=DYAI", "source_name": "Finviz", "published_at": "2026-05-30T23:09:49", "published_display": "30 May 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Scripps Research Partner to Accelerate Hantavirus Antibody and Vaccine Development Using C1 Biologic Platform", "summary": "Dyadic International, Inc. and Scripps Research have announced a collaboration to develop monoclonal antibody and vaccine candidates for hantaviruses, including the Andes virus, using Dyadic\u2019s C1 protein production platform. This partnership aims to address the urgent need for ra", "url": "https://www.minichart.com.sg/2026/05/28/dyadic-and-scripps-research-partner-to-accelerate-hantavirus-antibody-and-vaccine-development-using-c1-biologic-platform/", "source_name": "Minichart", "published_at": "2026-05-29T10:08:52", "published_display": "29 May 2026 10:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-scripps-research-collaborate-rapid-112500095.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:25:00+00:00", "published_display": "28 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skyline Corporate Communications Group, LLC Announces", "summary": "Skyline Corporate Communications Group, LLC announced that Dyadic International, Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, will present at the Skyline Signature Series\u2122 on Wednesday, May 27, 2026, at 12:00 PM ET. This live, interactive online event invites in", "url": "https://www.globenewswire.com/news-release/2026/05/21/3299699/0/en/skyline-corporate-communications-group-llc-announces-dyadic-applied-biosolutions-to-deliver-a-live-presentation-at-the-skyline-signature-series-on-wednesday-may-27-at-12-00-pm-et.html", "source_name": "GlobeNewswire", "published_at": "2026-05-24T13:10:18", "published_display": "24 May 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-participate-lytham-partners-spring-200500244.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T20:05:00+00:00", "published_display": "21 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series\u2122 on Wednesday, May 27 at 12:00 PM ET", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/skyline-corporate-communications-group-llc-194500136.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T19:45:00+00:00", "published_display": "21 May 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International\u2019s Earnings Call Shows Early Momentum", "summary": "Dyadic International (DYAI) reported a significant 182% year-over-year revenue increase in Q1 2026, reaching $1.1 million, driven by R&D, grant, and milestone revenues. The company announced several commercial product launches and expanded partnerships, while also demonstrating c", "url": "https://www.tipranks.com/news/company-announcements/dyadic-internationals-earnings-call-shows-early-momentum", "source_name": "TipRanks", "published_at": "2026-05-20T18:40:49", "published_display": "20 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Dyadic\u2019s Q1 2026 revenue surges 182% despite EPS miss", "summary": "Dyadic International Inc. reported a 182% increase in Q1 2026 revenue, reaching $1.1 million, despite an EPS loss of $0.05, meeting analyst forecasts. The stock, however, saw a 4.54% decline in after-hours trading due to investor concerns over operational losses and increased adm", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-dyadics-q1-2026-revenue-surges-182-despite-eps-miss-93CH-4698510", "source_name": "Investing.com", "published_at": "2026-05-20T14:10:47", "published_display": "20 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International stock (US26746E1055): Shares climb after recent momentum", "summary": "Dyadic International's shares (US26746E1055) recently climbed 5.07%, drawing attention to the small-cap biotechnology firm. This gain is attributed to renewed market momentum rather than a specific corporate announcement, highlighting the stock's sensitivity to sentiment and limi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-us26746e1055-shares-climb-after-recent/69351114", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T18:28:31", "published_display": "16 May 2026 18:28", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyadic International Earnings Call Highlights Early Momentum", "summary": "Dyadic International's Q1 earnings call revealed significant year-over-year revenue growth and several new product launches, signaling early commercialization momentum, particularly in biopharma, food, and bioindustrial markets. Despite improved operating losses and a solid cash ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DYAI/pressreleases/1968175/dyadic-international-earnings-call-highlights-early-momentum/", "source_name": "The Globe and Mail", "published_at": "2026-05-15T03:09:16", "published_display": "15 May 2026 03:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Dyadic International Q1 2026 revenue beats forecast, stock dips By Investing.com", "summary": "Dyadic International (DYAI) reported Q1 2026 revenue of $1.11 million, exceeding forecasts by 3.74%, while EPS met expectations at -$0.05. Despite the revenue beat and significant year-over-year growth, the stock dipped 1.8% in aftermarket trading due to ongoing operational losse", "url": "https://m.in.investing.com/news/stock-market-news/earnings-call-transcript-dyadic-international-q1-2026-revenue-beats-forecast-stock-dips-93CH-5404706?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-14T15:09:17", "published_display": "14 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyadic International (NASDAQ: DYAI) grows Q1 2026 revenue but flags going-concern risks", "summary": "Dyadic International (NASDAQ: DYAI) reported a significant increase in Q1 2026 revenue to $1.11 million, up from $393,572, driven by research collaborations, grants, and license milestones. Despite this growth and a slightly narrowed net loss of $1.95 million, the company faces s", "url": "https://www.stocktitan.net/sec-filings/DYAI/10-q-dyadic-international-inc-quarterly-earnings-report-4d6eb51434ba.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:38:54", "published_display": "13 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform", "summary": "Dyadic International, Inc. has announced a strategic partnership with Rabian BV to develop affordable rabies prophylactics and vaccines using Dyadic's proprietary C1 protein production platform. This collaboration, partially funded by Eurostars, aims to address the global burden ", "url": "https://www.globenewswire.com/fr/news-release/2024/02/28/2836955/0/en/Dyadic-Announces-Strategic-Partnership-Agreement-to-Develop-Affordable-Rabies-Prophylactics-and-Vaccines-Using-its-Proprietary-C1-Cell-Microbial-Protein-Production-Platform.html?utm_placement=navbharattimes.indiatimes.com%2F&utm_adgroup=teaching_kids_to_code_bmm", "source_name": "GlobeNewswire", "published_at": "2026-04-27T19:40:13", "published_display": "27 Apr 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyadic International stock (US26746E1055): Is its biotech platform strong enough to unlock new upside?", "summary": "Dyadic International leverages its C1 platform, a genetically engineered fungus, to produce biologics faster and cheaper than traditional methods, targeting the biopharmaceutical industry's need for efficient manufacturing. The company operates through licensing deals and collabo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-us26746e1055-is-its-biotech-platform-strong/69224963", "source_name": "AD HOC NEWS", "published_at": "2026-04-21T04:25:13", "published_display": "21 Apr 2026 04:25", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Stock: Biotechnology Innovator Focused on C1 Platform Amid Earnings Challenges", "summary": "Dyadic International is a Florida-based biotech firm leveraging its proprietary C1 fungal-based expression platform for scalable protein production across biopharmaceuticals, industrial enzymes, and agricultural bioactives. Despite ongoing losses and recent earnings challenges, t", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/dyadic-international-stock-biotechnology-innovator-focused-on-c1-platform/69058603", "source_name": "AD HOC NEWS", "published_at": "2026-04-02T17:40:27", "published_display": "02 Apr 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Dyadic International, Inc.'s (NASDAQ:DYAI) Path To Profitability", "summary": "Dyadic International, Inc. (NASDAQ:DYAI), a biotechnology platform company with a US$25m market cap, is projected by analysts to break even by 2027, turning a profit of US$1.9m after a final loss in 2026. This aggressive growth forecast of 121% year-on-year raises questions about", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyai/dyadic-international/news/dyadic-international-incs-nasdaqdyai-path-to-profitability", "source_name": "Simply Wall Street", "published_at": "2026-03-28T07:39:30", "published_display": "28 Mar 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (DYAI) Q4 2025 Earnings Call Transcript", "summary": "Dyadic International (DYAI) reported a shift from a development-stage company to a commercial-stage biotechnology business in Q4 2025. The company launched its first commercial products, secured strategic partnerships, and began generating recurring revenue streams. Despite a net", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/957662/dyadic-dyai-q4-2025-earnings-call-transcript/", "source_name": "The Globe and Mail", "published_at": "2026-03-25T17:23:00", "published_display": "25 Mar 2026 17:23", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... By GuruFocus", "summary": "Dyadic International Inc. (DYAI) reported its Q4 2025 earnings, highlighting a transition from a development-stage company to a commercial product-driven biotechnology business. Despite a decrease in total revenue to $3.09 million and an increased net loss of $7.36 million, the c", "url": "https://ca.investing.com/news/company-news/dyadic-international-inc-dyai-q4-2025-earnings-call-highlights-navigating-transition-with--4533712", "source_name": "Investing.com Canada", "published_at": "2026-03-25T17:00:00", "published_display": "25 Mar 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices", "summary": "Dyadic Applied BioSolutions has entered into an OEM distribution agreement with IBT Bioservices to commercialize its recombinant protein products. This partnership will utilize IBT's established sales channels, primarily focusing on recombinant DNase I and transferrin for researc", "url": "https://www.globenewswire.com/de/news-release/2026/03/16/3256153/0/en/Dyadic-Applied-BioSolutions-Announces-Commercial-Distribution-Partnership-with-IBT-Bioservices.html", "source_name": "GlobeNewswire", "published_at": "2026-03-17T04:09:54", "published_display": "17 Mar 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026", "summary": "Dyadic International, Inc. will report its financial results for the year ended December 31, 2025, and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. Eastern Time. The biotechnology company, known for its proprietary gene expression platforms, ", "url": "https://www.manilatimes.net/2026/03/12/tmt-newswire/globenewswire/dyadic-to-report-2025-full-year-financial-results-and-host-conference-call-on-wednesday-march-25-2026/2298291", "source_name": "The Manila Times", "published_at": "2026-03-15T10:39:59", "published_display": "15 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to detail full-year 2025 results in March 25 investor call", "summary": "Dyadic (Nasdaq: DYAI) announced it will report its full-year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. ET. Investors can join via dial-in or live webcast, with an archive available afterward on the company's Inve", "url": "https://www.stocktitan.net/news/DYAI/dyadic-to-report-2025-full-year-financial-results-and-host-s6a17y02ilku.html", "source_name": "Stock Titan", "published_at": "2026-03-10T11:39:11", "published_display": "10 Mar 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Animal-free enzyme from Dyadic and Fermbox targets gene therapy", "summary": "Dyadic Applied BioSolutions (NASDAQ: DYAI) and Fermbox Bio have launched their first commercial product under an expanded collaboration: an animal-origin-free Recombinant DNase I (RNase-free). This enzyme, currently available in research grade with a cGMP-grade version in develop", "url": "https://www.stocktitan.net/news/DYAI/dyadic-and-fermbox-bio-launch-first-product-under-expanded-v1xjkux9lsza.html", "source_name": "Stock Titan", "published_at": "2026-03-07T17:08:44", "published_display": "07 Mar 2026 17:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)", "summary": "Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This marks a significant step for Dyadic in transitioning towards commercial product expansion and re", "url": "https://www.globenewswire.com/news-release/2026/03/04/3249237/0/en/Dyadic-and-Fermbox-Bio-Launch-First-Product-Under-Expanded-Collaboration-Animal-Origin-Free-Recombinant-DNase-I-RNase-Free.html", "source_name": "GlobeNewswire", "published_at": "2026-03-04T07:20:00", "published_display": "04 Mar 2026 07:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Fermbox Bio Launch First Product Under Expanded", "summary": "Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This product, developed using Dyadic's microbial expression platforms and Fermbox Bio's biomanufactur", "url": "https://www.globenewswire.com/news-release/2026/03/04/3249237/0/en/dyadic-and-fermbox-bio-launch-first-product-under-expanded-collaboration-animal-origin-free-recombinant-dnase-i-rnase-free.html", "source_name": "GlobeNewswire", "published_at": "2026-03-04T07:20:00", "published_display": "04 Mar 2026 07:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone", "summary": "Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme for cheese production, after successfully completing final development activities. The achievement of this milestone earned Dyadic", "url": "https://www.globenewswire.com/de/news-release/2026/03/02/3247251/0/en/dyadic-applied-biosolutions-and-inzymes-aps-announce-planned-2026-commercialization-of-non-animal-dairy-enzyme-following-achievement-of-development-milestone.html", "source_name": "GlobeNewswire", "published_at": "2026-03-02T18:51:53", "published_display": "02 Mar 2026 18:51", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Animal-free cheese enzyme set for 2026 launch in $2B dairy market", "summary": "Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production, a key enzyme in the $1.5-2.0 billion global dairy processing enzyme market. This follows the successful completion of dev", "url": "https://www.stocktitan.net/news/DYAI/dyadic-applied-bio-solutions-and-inzymes-ap-s-announce-planned-2026-81aeev3k6w2f.html", "source_name": "Stock Titan", "published_at": "2026-03-02T11:51:25", "published_display": "02 Mar 2026 11:51", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQUVpSlBIWDlfOGdvVGtqdmpiNldrdWlfWXFUQk43WU95Sk1pUEo3M3FvWDJseUdIN3Z5WUJpUTRrTXN6N0ZKT05xa1ZoRjRIRU1XTnBnWXN3QnBhQVVOVmtGOHB3LVJQNzZMLUt4Q2d5M1Noa0tVNFY0OXA1RUV6bjI1aXZJSWpNdUJHQXFQYmZVcGpTMGp4ZTdjMk5TYzVwdHBPUlZSUVB1TnhWbG1XUnZ0SWl5ZmtrQlVsRTM2Skx2WEhZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-31T07:00:00+00:00", "published_display": "31 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International (DYAI) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9BOVhaQ3BENlkxczhVeVh4Mk1salVyNmEyd19TSWpxNVhYVjhHd1lyeDJoVnctSUp3U0JOM3BKVl9lOFlqZmZ1RFg3NGk0YzIwWGpmVTcxT1daeEtSMlF6Q2pPZmNMZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:13:33+00:00", "published_display": "11 May 2024 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International (DYAI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wc0ZNN2lacEQ3eWRsa212dlpfamRMUWk5NHVtZXh0dnBWSWlWTDBmODBGdmlNcFYxRDFvNHdUcENWYVVJTlJKOFBuV2plVkRKVnBVQnBfR041QQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T05:46:55+00:00", "published_display": "16 Aug 2016 05:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to sales forward of Dyadic International, Inc. \u2013 NASDAQ:DYAI", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPVm1sOVVLdTc2blpaYzZ3UmV4UU5DXzBuQ0ctbElVMnAxUHl3a0R5NjFKa0FuZ1NYZ3Y5UW9nRGlsd2FWTWVlUUNzY3hnRllwNktHWVFqTnU5ZmZYQi1LOGJGWUdwQ1RvWDlOc2g5NUZ1VGo1d2dzR0V3cTM1cGhySTYzY3Q3NjlQVHA1aE5CU3VkRVZXTnBCbXhOcVFSZw?oc=5", "source_name": "TradingView", "published_at": "2026-07-13T20:33:38+00:00", "published_display": "13 Jul 2026 20:33", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Expect Breakeven For Dyadic International, Inc. (NASDAQ:DYAI) Before Long", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxNa3ZMYnNEUU5JYXJ6aXUtSHRrbGRJQm16VEJDdzFsQUd4bWlZWm9SRHlaRmVNRFo3dlhkZlNHS3hIczRXdkNJQjZpSmR6bFZHZ05uOF9qYVZUOWt6VnlOdktoWUpJWXJvQkZGVHRLMXZqNWQ4aVlQNnBmWUxoc1hXSUV4bFFoUlBTM3BremV3Z01ZRWxkMExveU9GelljdGtOdlBVQnI1YUM0SnFXZV94UjBJWlhMZ0xVTktLd3N1Nzc4ZVg4TUR5ajFBd3h1NFBFM1NON0Y5bmlTZDB4aHNtTllXMVk3eWpEZWfSAe8BQVVfeXFMUGY3SUZUaGVNbmNLZlkwMkZ5VkJBQlRxeWVOMFV2Vks3alAyM3FRRVdOc2tRTU5zMXliTEpYbkx2aTBoU0U3SEFJMVVVSjc1aG94UV9TX1dmZTItc0NjQWZ5dXlRTUNXOVNHaTJONkZ1QzBfTk1mSnEtMWl6Vkc3REZ2Z2xDc2R0dUZZaWNRa3FJZDJlRTY0YUJSWEV1VmJxYmNENkxTRERxVE5DUlo5eUd0TENFeHZVNkRZWFNHSjJSb3M1US1KUVo1Y0x0V3FPUnpWX1kyWkwxZm12SENfZzhlMmVFNGJqc29NT2ttQW8?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-11T13:30:59+00:00", "published_display": "11 Jul 2026 13:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Q1 2026 Earnings: Continued Losses as Pre-Revenue Company Advances C1 Platform; Shares Rise 4.82% - Interim Report", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7AFBVV95cUxOb0I1LUhDY2JCeWtXOTl6TDlvYXlfU0hVeWVkYkkyQ3NQZ1hUZWV2c1ExRTdXaGJWdXNobVF6M21tTEhSVVdEbHVLV2MxZ2pCNVdTTmRkRnlRbVQwblY5ZFR4VmFPdzJmeDlNbDhqQU5HRmZNTU4ydG1nRFR0TVNCVG00R3VYREQxT0ZYa2lhY1E5SzBFdTdHWk1Say1OSGYybTNuQmFsTjJqb2oyckxmNDJaSmNxNnpaajZSMVBQM0NkTG9yeHpjNGxyblhBSHhSaHlfN0MtSWNteEZGRzFfVmRVVkpyWTlRTklxag?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-09T17:47:15+00:00", "published_display": "09 Jul 2026 17:47", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Craig-Hallum Maintains Dyadic(DYAI.US) With Buy Rating", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQUUhhVDFJeDBxZGZmcjJKU3hzSlZBNVYzdFMxSGZoNW0yeUNwaFUwemJsYmVLWTVuMXZPel95RTlxUl9IOE1xTDNDeWEtcFJuNXE2aGFQenNSM0d0YUY4b1dzekxPeG1UNVUwOERvLVcxaU85Vm5RZUdYby1DMkZhRTRndC1TSEUtbWZPdHoxUWlSMGNJNlBaSg?oc=5", "source_name": "\u5bcc\u9014\u725b\u725b", "published_at": "2026-07-08T19:48:53+00:00", "published_display": "08 Jul 2026 19:48", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International stock reflects a thin catalyst day. Focus stays on its enzyme platform.", "summary": "Dyadic International (DYAI) stock is focused on its enzyme platform business, with no new catalysts reported. The company utilizes fungal expression and recombinant protein development for industrial and life-science applications. Its value is tied to platform development, licens", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-reflects-a-thin-catalyst-day-focus-stays-on/69714994", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T16:24:00", "published_display": "07 Jul 2026 16:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Progresses Multiple Protein Production Partnerships", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-international-progresses-multiple-protein-133230260.html", "source_name": "MT Newswires", "published_at": "2026-07-07T13:32:30+00:00", "published_display": "07 Jul 2026 13:32", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Global Collaborations Continue to Validate Dyadic\u2019s C1 Platform and Expands Commercial Potential", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/global-collaborations-continue-validate-dyadic-112500240.html", "source_name": "GlobeNewswire", "published_at": "2026-07-07T11:25:00+00:00", "published_display": "07 Jul 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic says its C1 platform can make antibodies and vaccines faster", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNZ2c3UHU4UEI1aWZUNDFPMldmX0hoZkNrM2duSDllTUZwVF95aUVkTVVtRXZhWnMxNW5pNHVoSnlOS3dhWDhyaTZySVpHbkRVT0Fua1lkNGRkRzJpUWVkU1NBMWJoeng5a3VnUXh5d0NJUUhFSExXNEFoZW5jNjYzd19uaFFBLVNkUERXZFFJYm5LWnl3MWUteXAwN2dlUVFJMlBsdXgzaU9aOXVTZF9GV3k4bENEdnN4UUxXejE5Yw?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-07T11:25:00+00:00", "published_display": "07 Jul 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYAI - Dyadic International Inc, DE Forecast, Target Price", "summary": "This article provides a detailed financial overview of Dyadic International Inc (DYAI), including key metrics such as market capitalization, income, sales, EPS, and various performance indicators. It also lists the last closing price, daily change, and a target price set at $6.00", "url": "https://finviz.com/stock?t=DYAI&ta=1&p=d&ty=fc", "source_name": "Finviz", "published_at": "2026-07-06T13:47:09", "published_display": "06 Jul 2026 13:47", "sentiment": "positive", "sentiment_pct": 60, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francisco Trust (DYAI) amends large convertible note and sells DYADIC shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQSS1yT25aUkN5VWVQRkN2NnpkcW4wNnJSX2M4OTB3NUVNUkZFc3FWXzZxYzIzWWZZeWdnTU1WOWNtT2tiV2ZDTzR6U2JtSlVkQ2F2SFgzdE8tVmhsdVZlUTFzUjdTb1dCMkNXa0RmOEcxR3Rkc3JVcGRURUMybWhwaUZMYkN5YmJtZ2ZGQTZtZEJST2F0WEJZandFeW5fT3F0UzJBdm81LXE1QUYzamJCTzh5bVgtaFBiUnc?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T10:30:45+00:00", "published_display": "06 Jul 2026 10:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYADIC International (NASDAQ: DYAI) trustee reports 11.58% stake in 13G/A", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQX2VPZldCOXMza3dLZ1lvNFpfMXRZNnc1cUwxNTVPcnU2WDNxZUlsRmhLeEQtWkRmM1RReDJZSDN3QlcyUnBKUWRUbkdJQjFsNldFMzFSeFVpY1lYR2E4Y3diRVpNaGtCOU1QM3N0VXBOdk5WVXFMWS1qVEF0Q3cxbmJJWkpXSHVTNXZITkxXbkxVRGJCX2hHaVByajVRcWZSRXY4TXVkMHV0NVZXeFprRFlodkd3ZWlsQUhPbGF6bXp4RnhwQXJ2NXJHNA?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Dyadic International Inc For: 6 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxONUFCNUVjaUxuRVktMkRkZnJ0MkJMVG1lVGluSktmbDlBZmhoSTlJeF9mLVlKZGROLWJPaFZYWmpvYUd4azJHMnBocThaNjg0U3dTTTd0eW8xOU9ZbTFtQUR6eU9WZ1ZSSkVJam9LM0VWZGZNX1NwRGpLaGRYNFRaZDRseXpHbWgzLVl4SHhmRGJFZzY2R25PUVd1dUliLW1WdWpwTE53?oc=5", "source_name": "Investing.com Nigeria", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Francisco Trust sells $343,763 in Dyadic International shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxOd2JuTzRQcDczeGE2dl9uRk1wWVdCVTFIOHE1YXJMQy1Zb2FHVlVnS1pUTzNtbXFwTTFxWTFBWnNlN2plMlU1RUJmMXQ4NVRNOG9ZSzhTR3NPaUdNXzZrS1c3UEtCUlJ5dTVzNmthd2FOTE9tMmlSMVVNV2xuZU1JQTlaUFdsMlI5ZS1vSlZ3b3lJMjdBNVF6TDVNU1BBQkZtajM5WE42bUZBSHBBT1g1b3M1amtzV3BhZWFGVUhkMWZEUQ?oc=5", "source_name": "Investing.com", "published_at": "2026-07-06T07:00:00+00:00", "published_display": "06 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Receives Japan Patent Allowance for Recombinant Protein Expression Technology", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-international-receives-japan-patent-121307575.html", "source_name": "MT Newswires", "published_at": "2026-06-29T12:13:07+00:00", "published_display": "29 Jun 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Expands IP Protection and Business Development Activities in Japan", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/dyadic-expands-ip-protection-business-112500388.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:25:00+00:00", "published_display": "29 Jun 2026 11:25", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Japan backs Dyadic\u2019s protein technology as it courts partners", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxObE5nNThKaWJGSTBRR3dRVnh1YWZSbnZvYl9OczdmM3c1cjFOdHdBQWJmWGNqU21pZndPU1ZORE1hbnVzWmhkdU9sOExQRGlXQmlDX0hLWFlDaHMwYkl5c2Vmb2I4czZSTENTRFFtWUFSd1c5bnJHLU1pUzN0cnRSaDBXMmg1QlR2Qk1rdlk1NlFDX3k5ZHhJVkJMRk5ua3dtTWZkYUR2aTVNRUJyVWFNUl9qSUtPR2o3WmU3SU90NA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "An Interview with the President & COO: How Dyadic is Commercializing Its Protein Platform Across Multi-Billion-Dollar Markets", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/interview-president-coo-dyadic-commercializing-124600451.html", "source_name": "TMX Newsfile", "published_at": "2026-06-22T12:46:00+00:00", "published_display": "22 Jun 2026 12:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (NASDAQ: DYAI) investors OK reverse split, pay plan and auditor", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxNVXh2NWNLaXdBaGp0emVxOHhtdk9qeWQ4MmwwN1d1TXVsc01ZZUZSNW1SNU9CSy14cmNGOXZSc1pOSGxCVmx3cTY2Z3k2NklpU0NJSi1Xdi1QYzBtODhSSDdoSkVyN2liN0NkSk1iOFFlTEZrdjhOS0RHWlNmeV9keDNjcE15R0hNcDFEYldZSXBndDF1bjNIWDBmMVJUczRGU0VobTNnNlotU2xnelgydXBSSQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Nasdaq warns Dyadic (NASDAQ: DYAI) over bid price and listing shortfalls", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxQaHFYWnMyYy1ndWpkUzZtUlI1ZjEtRWxCTF9VejFTMHNFdGJtVENmaTM5emRiMnozXy1tRTZ0STQ1czdhVzdGTlVPYmd0bWdVNVI5RVV5OEo2T2c0dWlGc1F0OWJGaC0tTEF3M0U2Z2NjU2hNQ0NkRUNxNGttdHVqU2dZWTE4N01lQjZOLTJTbklPcXNMTDV1cC1TWG9abXhnaUlsNjJzZFZjUzBnRzRHNHpBUQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Highlights Accelerated Interest in C1 Biomanufacturing Platform Amid Ebola Preparedness Activities and Growing Commercial Adoption", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-highlights-accelerated-interest-c1-112500620.html", "source_name": "GlobeNewswire", "published_at": "2026-06-15T11:25:00+00:00", "published_display": "15 Jun 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[8-K] DYADIC INTERNATIONAL INC Reports Material Event | DYAI 8-K Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOSGtydTBlMmRSZEpZUmRHMG9kYlZXUG1weHNseGlIblQtVEQ4Q1ZNcHZpM1BhekFNaWp3clNyOWdzRllDR3BkQkdtR1ZOVXJXMUxSbkVOTlhqaFJzQVF1VmZlT1Q3WUZtbVFoaVFhTXBPc0NyUVNTUHhjY2VVZmlJUThsQ3NvTW90Mm5HaUw4clRvb1VCMVI4M3ZOMkVoQjNsOWR5MkdLNk41NGNqRGFwY0RXVQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "From viral gene to antibody in 15 days: Dyadic\u2019s Ebola bet", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNZ0VJd2c3VEpBTDVoeDdjSVBFZ3RUQmtYc0hpU0xnMmtGRWthYS13SWRQdlZFVDdGRnR6d08zNy1tZTNVWjk5Z1VIeFBXLTVxTFltOHJLVzlVVW1CS1R3UVdRem56MmVkV0F2NGwxZEQ1bVJrbGtkNkl0Zm13aXNTNGVaV2FhaVZhMVRjSkhiUEx5YUF3YjlyVGswVnktVmpjTW13MWJhaDgxVC1Ta0FodU1hTDM3ajA?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (DYAI) Q1 2026 Earnings Call Transcript", "summary": "", "url": "https://finance.yahoo.com/m/18721462-f4d5-3665-bbe9-63e27f22e1cc/dyadic-%28dyai%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-06-02T16:39:07+00:00", "published_display": "02 Jun 2026 16:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "DYAI - Dyadic International Inc, DE Stock Price and Quote", "summary": "This article provides a detailed stock quote and financial overview for Dyadic International Inc (DYAI), a healthcare biotechnology company. It includes key financial metrics, recent news headlines, analyst ratings, and insider transaction data. The company's stock closed at $0.8", "url": "https://finviz.com/stock?t=DYAI", "source_name": "Finviz", "published_at": "2026-05-30T23:09:49", "published_display": "30 May 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Scripps Research Partner to Accelerate Hantavirus Antibody and Vaccine Development Using C1 Biologic Platform", "summary": "Dyadic International, Inc. and Scripps Research have announced a collaboration to develop monoclonal antibody and vaccine candidates for hantaviruses, including the Andes virus, using Dyadic\u2019s C1 protein production platform. This partnership aims to address the urgent need for ra", "url": "https://www.minichart.com.sg/2026/05/28/dyadic-and-scripps-research-partner-to-accelerate-hantavirus-antibody-and-vaccine-development-using-c1-biologic-platform/", "source_name": "Minichart", "published_at": "2026-05-29T10:08:52", "published_display": "29 May 2026 10:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-scripps-research-collaborate-rapid-112500095.html", "source_name": "GlobeNewswire", "published_at": "2026-05-28T11:25:00+00:00", "published_display": "28 May 2026 11:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skyline Corporate Communications Group, LLC Announces", "summary": "Skyline Corporate Communications Group, LLC announced that Dyadic International, Inc. (Nasdaq: DYAI), operating as Dyadic Applied BioSolutions, will present at the Skyline Signature Series\u2122 on Wednesday, May 27, 2026, at 12:00 PM ET. This live, interactive online event invites in", "url": "https://www.globenewswire.com/news-release/2026/05/21/3299699/0/en/skyline-corporate-communications-group-llc-announces-dyadic-applied-biosolutions-to-deliver-a-live-presentation-at-the-skyline-signature-series-on-wednesday-may-27-at-12-00-pm-et.html", "source_name": "GlobeNewswire", "published_at": "2026-05-24T13:10:18", "published_display": "24 May 2026 13:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/dyadic-participate-lytham-partners-spring-200500244.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T20:05:00+00:00", "published_display": "21 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Skyline Corporate Communications Group, LLC Announces Dyadic Applied BioSolutions to Deliver a Live Presentation at the Skyline Signature Series\u2122 on Wednesday, May 27 at 12:00 PM ET", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/skyline-corporate-communications-group-llc-194500136.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T19:45:00+00:00", "published_display": "21 May 2026 19:45", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International\u2019s Earnings Call Shows Early Momentum", "summary": "Dyadic International (DYAI) reported a significant 182% year-over-year revenue increase in Q1 2026, reaching $1.1 million, driven by R&D, grant, and milestone revenues. The company announced several commercial product launches and expanded partnerships, while also demonstrating c", "url": "https://www.tipranks.com/news/company-announcements/dyadic-internationals-earnings-call-shows-early-momentum", "source_name": "TipRanks", "published_at": "2026-05-20T18:40:49", "published_display": "20 May 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Dyadic\u2019s Q1 2026 revenue surges 182% despite EPS miss", "summary": "Dyadic International Inc. reported a 182% increase in Q1 2026 revenue, reaching $1.1 million, despite an EPS loss of $0.05, meeting analyst forecasts. The stock, however, saw a 4.54% decline in after-hours trading due to investor concerns over operational losses and increased adm", "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-dyadics-q1-2026-revenue-surges-182-despite-eps-miss-93CH-4698510", "source_name": "Investing.com", "published_at": "2026-05-20T14:10:47", "published_display": "20 May 2026 14:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International stock (US26746E1055): Shares climb after recent momentum", "summary": "Dyadic International's shares (US26746E1055) recently climbed 5.07%, drawing attention to the small-cap biotechnology firm. This gain is attributed to renewed market momentum rather than a specific corporate announcement, highlighting the stock's sensitivity to sentiment and limi", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-us26746e1055-shares-climb-after-recent/69351114", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T18:28:31", "published_display": "16 May 2026 18:28", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Earnings Call Highlights Early Momentum", "summary": "Dyadic International's Q1 earnings call revealed significant year-over-year revenue growth and several new product launches, signaling early commercialization momentum, particularly in biopharma, food, and bioindustrial markets. Despite improved operating losses and a solid cash ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/DYAI/pressreleases/1968175/dyadic-international-earnings-call-highlights-early-momentum/", "source_name": "The Globe and Mail", "published_at": "2026-05-15T03:09:16", "published_display": "15 May 2026 03:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Dyadic International Q1 2026 revenue beats forecast, stock dips By Investing.com", "summary": "Dyadic International (DYAI) reported Q1 2026 revenue of $1.11 million, exceeding forecasts by 3.74%, while EPS met expectations at -$0.05. Despite the revenue beat and significant year-over-year growth, the stock dipped 1.8% in aftermarket trading due to ongoing operational losse", "url": "https://m.in.investing.com/news/stock-market-news/earnings-call-transcript-dyadic-international-q1-2026-revenue-beats-forecast-stock-dips-93CH-5404706?ampMode=1", "source_name": "Investing.com India", "published_at": "2026-05-14T15:09:17", "published_display": "14 May 2026 15:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International (NASDAQ: DYAI) grows Q1 2026 revenue but flags going-concern risks", "summary": "Dyadic International (NASDAQ: DYAI) reported a significant increase in Q1 2026 revenue to $1.11 million, up from $393,572, driven by research collaborations, grants, and license milestones. Despite this growth and a slightly narrowed net loss of $1.95 million, the company faces s", "url": "https://www.stocktitan.net/sec-filings/DYAI/10-q-dyadic-international-inc-quarterly-earnings-report-4d6eb51434ba.html", "source_name": "Stock Titan", "published_at": "2026-05-13T20:38:54", "published_display": "13 May 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform", "summary": "Dyadic International, Inc. has announced a strategic partnership with Rabian BV to develop affordable rabies prophylactics and vaccines using Dyadic's proprietary C1 protein production platform. This collaboration, partially funded by Eurostars, aims to address the global burden ", "url": "https://www.globenewswire.com/fr/news-release/2024/02/28/2836955/0/en/Dyadic-Announces-Strategic-Partnership-Agreement-to-Develop-Affordable-Rabies-Prophylactics-and-Vaccines-Using-its-Proprietary-C1-Cell-Microbial-Protein-Production-Platform.html?utm_placement=navbharattimes.indiatimes.com%2F&utm_adgroup=teaching_kids_to_code_bmm", "source_name": "GlobeNewswire", "published_at": "2026-04-27T19:40:13", "published_display": "27 Apr 2026 19:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International stock (US26746E1055): Is its biotech platform strong enough to unlock new upside?", "summary": "Dyadic International leverages its C1 platform, a genetically engineered fungus, to produce biologics faster and cheaper than traditional methods, targeting the biopharmaceutical industry's need for efficient manufacturing. The company operates through licensing deals and collabo", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/dyadic-international-stock-us26746e1055-is-its-biotech-platform-strong/69224963", "source_name": "AD HOC NEWS", "published_at": "2026-04-21T04:25:13", "published_display": "21 Apr 2026 04:25", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Stock: Biotechnology Innovator Focused on C1 Platform Amid Earnings Challenges", "summary": "Dyadic International is a Florida-based biotech firm leveraging its proprietary C1 fungal-based expression platform for scalable protein production across biopharmaceuticals, industrial enzymes, and agricultural bioactives. Despite ongoing losses and recent earnings challenges, t", "url": "https://www.ad-hoc-news.de/boerse/ueberblick/dyadic-international-stock-biotechnology-innovator-focused-on-c1-platform/69058603", "source_name": "AD HOC NEWS", "published_at": "2026-04-02T17:40:27", "published_display": "02 Apr 2026 17:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International, Inc.'s (NASDAQ:DYAI) Path To Profitability", "summary": "Dyadic International, Inc. (NASDAQ:DYAI), a biotechnology platform company with a US$25m market cap, is projected by analysts to break even by 2027, turning a profit of US$1.9m after a final loss in 2026. This aggressive growth forecast of 121% year-on-year raises questions about", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dyai/dyadic-international/news/dyadic-international-incs-nasdaqdyai-path-to-profitability", "source_name": "Simply Wall Street", "published_at": "2026-03-28T07:39:30", "published_display": "28 Mar 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic (DYAI) Q4 2025 Earnings Call Transcript", "summary": "Dyadic International (DYAI) reported a shift from a development-stage company to a commercial-stage biotechnology business in Q4 2025. The company launched its first commercial products, secured strategic partnerships, and began generating recurring revenue streams. Despite a net", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Motley%20Fool/957662/dyadic-dyai-q4-2025-earnings-call-transcript/", "source_name": "The Globe and Mail", "published_at": "2026-03-25T17:23:00", "published_display": "25 Mar 2026 17:23", "sentiment": "positive", "sentiment_pct": 67, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International Inc (DYAI) Q4 2025 Earnings Call Highlights: Navigating Transition with ... By GuruFocus", "summary": "Dyadic International Inc. (DYAI) reported its Q4 2025 earnings, highlighting a transition from a development-stage company to a commercial product-driven biotechnology business. Despite a decrease in total revenue to $3.09 million and an increased net loss of $7.36 million, the c", "url": "https://ca.investing.com/news/company-news/dyadic-international-inc-dyai-q4-2025-earnings-call-highlights-navigating-transition-with--4533712", "source_name": "Investing.com Canada", "published_at": "2026-03-25T17:00:00", "published_display": "25 Mar 2026 17:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices", "summary": "Dyadic Applied BioSolutions has entered into an OEM distribution agreement with IBT Bioservices to commercialize its recombinant protein products. This partnership will utilize IBT's established sales channels, primarily focusing on recombinant DNase I and transferrin for researc", "url": "https://www.globenewswire.com/de/news-release/2026/03/16/3256153/0/en/Dyadic-Applied-BioSolutions-Announces-Commercial-Distribution-Partnership-with-IBT-Bioservices.html", "source_name": "GlobeNewswire", "published_at": "2026-03-17T04:09:54", "published_display": "17 Mar 2026 04:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026", "summary": "Dyadic International, Inc. will report its financial results for the year ended December 31, 2025, and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. Eastern Time. The biotechnology company, known for its proprietary gene expression platforms, ", "url": "https://www.manilatimes.net/2026/03/12/tmt-newswire/globenewswire/dyadic-to-report-2025-full-year-financial-results-and-host-conference-call-on-wednesday-march-25-2026/2298291", "source_name": "The Manila Times", "published_at": "2026-03-15T10:39:59", "published_display": "15 Mar 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic to detail full-year 2025 results in March 25 investor call", "summary": "Dyadic (Nasdaq: DYAI) announced it will report its full-year 2025 financial results and host a corporate update conference call on Wednesday, March 25, 2026, at 5:00 p.m. ET. Investors can join via dial-in or live webcast, with an archive available afterward on the company's Inve", "url": "https://www.stocktitan.net/news/DYAI/dyadic-to-report-2025-full-year-financial-results-and-host-s6a17y02ilku.html", "source_name": "Stock Titan", "published_at": "2026-03-10T11:39:11", "published_display": "10 Mar 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Animal-free enzyme from Dyadic and Fermbox targets gene therapy", "summary": "Dyadic Applied BioSolutions (NASDAQ: DYAI) and Fermbox Bio have launched their first commercial product under an expanded collaboration: an animal-origin-free Recombinant DNase I (RNase-free). This enzyme, currently available in research grade with a cGMP-grade version in develop", "url": "https://www.stocktitan.net/news/DYAI/dyadic-and-fermbox-bio-launch-first-product-under-expanded-v1xjkux9lsza.html", "source_name": "Stock Titan", "published_at": "2026-03-07T17:08:44", "published_display": "07 Mar 2026 17:08", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)", "summary": "Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This marks a significant step for Dyadic in transitioning towards commercial product expansion and re", "url": "https://www.globenewswire.com/news-release/2026/03/04/3249237/0/en/Dyadic-and-Fermbox-Bio-Launch-First-Product-Under-Expanded-Collaboration-Animal-Origin-Free-Recombinant-DNase-I-RNase-Free.html", "source_name": "GlobeNewswire", "published_at": "2026-03-04T07:20:00", "published_display": "04 Mar 2026 07:20", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic and Fermbox Bio Launch First Product Under Expanded", "summary": "Dyadic Applied BioSolutions and Fermbox Bio have launched their first commercial product, animal-origin-free Recombinant DNase I (RNase-free), under their expanded collaboration. This product, developed using Dyadic's microbial expression platforms and Fermbox Bio's biomanufactur", "url": "https://www.globenewswire.com/news-release/2026/03/04/3249237/0/en/dyadic-and-fermbox-bio-launch-first-product-under-expanded-collaboration-animal-origin-free-recombinant-dnase-i-rnase-free.html", "source_name": "GlobeNewswire", "published_at": "2026-03-04T07:20:00", "published_display": "04 Mar 2026 07:20", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone", "summary": "Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin, a key enzyme for cheese production, after successfully completing final development activities. The achievement of this milestone earned Dyadic", "url": "https://www.globenewswire.com/de/news-release/2026/03/02/3247251/0/en/dyadic-applied-biosolutions-and-inzymes-aps-announce-planned-2026-commercialization-of-non-animal-dairy-enzyme-following-achievement-of-development-milestone.html", "source_name": "GlobeNewswire", "published_at": "2026-03-02T18:51:53", "published_display": "02 Mar 2026 18:51", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Animal-free cheese enzyme set for 2026 launch in $2B dairy market", "summary": "Dyadic Applied BioSolutions and Inzymes ApS have announced the planned 2026 commercialization of recombinant non-animal bovine chymosin for cheese production, a key enzyme in the $1.5-2.0 billion global dairy processing enzyme market. This follows the successful completion of dev", "url": "https://www.stocktitan.net/news/DYAI/dyadic-applied-bio-solutions-and-inzymes-ap-s-announce-planned-2026-81aeev3k6w2f.html", "source_name": "Stock Titan", "published_at": "2026-03-02T11:51:25", "published_display": "02 Mar 2026 11:51", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International, Inc. Announces Pricing of $5.75 Million Public Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxPQUVpSlBIWDlfOGdvVGtqdmpiNldrdWlfWXFUQk43WU95Sk1pUEo3M3FvWDJseUdIN3Z5WUJpUTRrTXN6N0ZKT05xa1ZoRjRIRU1XTnBnWXN3QnBhQVVOVmtGOHB3LVJQNzZMLUt4Q2d5M1Noa0tVNFY0OXA1RUV6bjI1aXZJSWpNdUJHQXFQYmZVcGpTMGp4ZTdjMk5TYzVwdHBPUlZSUVB1TnhWbG1XUnZ0SWl5ZmtrQlVsRTM2Skx2WEhZ?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-07-31T07:00:00+00:00", "published_display": "31 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International (DYAI) Stock Forecast and Price Target 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiZkFVX3lxTE9BOVhaQ3BENlkxczhVeVh4Mk1salVyNmEyd19TSWpxNVhYVjhHd1lyeDJoVnctSUp3U0JOM3BKVl9lOFlqZmZ1RFg3NGk0YzIwWGpmVTcxT1daeEtSMlF6Q2pPZmNMZw?oc=5", "source_name": "MarketBeat", "published_at": "2024-05-11T15:13:33+00:00", "published_display": "11 May 2024 15:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dyadic International (DYAI) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE1wc0ZNN2lacEQ3eWRsa212dlpfamRMUWk5NHVtZXh0dnBWSWlWTDBmODBGdmlNcFYxRDFvNHdUcENWYVVJTlJKOFBuV2plVkRKVnBVQnBfR041QQ?oc=5", "source_name": "MarketBeat", "published_at": "2016-08-16T05:46:55+00:00", "published_display": "16 Aug 2016 05:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 60, "sentiment_summary": {"positive": 19, "negative": 2, "neutral": 39, "score": 57, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 17.05, "count": 31}, {"event": "earnings", "label": "Earnings", "weight": 11.0, "count": 22}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 19, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 1.06, "latest_week": "2026-07-10", "one_week_move": 12.7, "four_week_move": 55.4, "twelve_week_move": 21.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.65265, "market_dynamics_buy_signal": false, "relative_strength": 0.064537, "fair_value_gap": -18.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.3636, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+12.7% over one week, +55.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "GlobeNewswire", "count": 12}, {"label": "Stock Titan", "count": 12}, {"label": "Market source", "count": 5}, {"label": "AD HOC NEWS", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "TradingView", "count": 2}, {"label": "MT Newswires", "count": 2}, {"label": "Finviz", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 31}, {"label": "Earnings", "count": 22}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "57/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+12.7% over one week, +55.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to sales forward of Dyadic International, Inc. \u2013 NASDAQ:DYAI"}], "updated_at": "2026-07-16T04:34:59.057430+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}